SCYNEXIS (SCYX)
NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Price & Analysis

1,380 Followers

SCYX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.15 - $4.10
Previous Close$1.82
Volume212.66K
Average Volume (3M)417.50K
Market Cap
$56.50M
Enterprise Value$8.87M
Total Cash (Recent Filing)$96.09M
Total Debt (Recent Filing)$48.46M
Price to Earnings (P/E)-0.8
Beta1.48
May 10, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding32,656,992
10 Day Avg. Volume2,020,828
30 Day Avg. Volume417,503
Standard Deviation0.24
R-Squared0.20
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.55
Price to Sales (P/S)16.66
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit0.69
Enterprise Value/Ebitda-0.12
Forecast
Price Target Upside798.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

SCYX FAQ

What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $1.15 and its highest was $4.10 in the past 12 months.
    What is SCYNEXIS’s market cap?
    Currently, no data Available
    When is SCYNEXIS’s upcoming earnings report date?
    SCYNEXIS’s upcoming earnings report date is May 10, 2023 which is in 41 days.
      How were SCYNEXIS’s earnings last quarter?
      Currently, no data Available
      Is SCYNEXIS overvalued?
      According to Wall Street analysts SCYNEXIS’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does SCYNEXIS pay dividends?
        SCYNEXIS does not currently pay dividends.
        What is SCYNEXIS’s EPS estimate?
        SCYNEXIS’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does SCYNEXIS have?
        SCYNEXIS has 32,656,994 shares outstanding.
          What happened to SCYNEXIS’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of SCYNEXIS?
          Among the largest hedge funds holding SCYNEXIS’s share is Scion Asset Management. It holds SCYNEXIS’s shares valued at N/A.

            ---

            SCYNEXIS Stock Smart Score

            The SCYNEXIS stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
            Learn more about TipRanks Smart Score

            Company Description

            SCYNEXIS

            SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

            ---

            Top 5 ETFs holding SCYX

            Name
            Market Value
            Smart Score
            iShares Core S&P Total U.S. Stock Market ETF
            8
            Up to five ETFs with an Outperform Smart Score that hold SCYX. The ETFs are listed according to market value of SCYX within the ETF

            ---

            Forecast EPS vs Actual EPS

            Currently, no data available
            Please return soon. This page is being updated.

            Similar Stocks
            Company
            Price & Change
            Follow
            Longboard Pharmaceuticals
            Ikena Oncology
            Seelos Therapeutics
            MyMD Pharmaceuticals

            Popular Stocks

            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis